Evidence map›Paper›PMID 36865273›Full record

ArticlebioRxiv : the preprint server for biology2023

MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression.

Jiayu Chen, Qizhi Zheng, Jessica L Hicks, Levent Trabzonlu, Busra Ozbek, Tracy Jones, Ajay Vaghasia, Tatianna C Larman, Rulin Wang, Mark C Markowski and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Jiayu ChenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Qizhi ZhengDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jessica L HicksDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Levent TrabzonluDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Busra OzbekDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tracy JonesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ajay VaghasiaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tatianna C LarmanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rulin WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mark C MarkowskiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sam R DenmeadeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kenneth J PientaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ralph H HrubanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Emmanuel S AntonarakisDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anuj GuptaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Chi V DangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Srinivasan YegnasubramanianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Translational imaging biomarkers of the tumor microenvironment in early prostate cancerU54CA274370 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANGELO Michael DE MARZO · 2022 to 2026
$9.1M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236NCI NIH HHS U01 CA196390NCI NIH HHS U54 CA274370
6 · The paper itself

Abstract

Increased mitochondrial function may render some cancers vulnerable to mitochondrial inhibitors. Since mitochondrial function is regulated partly by mitochondrial DNA copy number (mtDNAcn), accurate measurements of mtDNAcn could help reveal which cancers are driven by increased mitochondrial function and may be candidates for mitochondrial inhibition. However, prior studies have employed bulk macrodissections that fail to account for cell type-specific or tumor cell heterogeneity in mtDNAcn. These studies have often produced unclear results, particularly in prostate cancer. Herein, we developed a multiplex

Identifiers

PMID36865273
PMCPMC9979994
OpenAlexW4321434883

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.